For research use only. Not for therapeutic Use.
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer[1][2][3].
Racotumomab induces a specific humoral and cellular immune response against the NeuGcGM3 ganglioside present in tumor cells, stimulating the cell death[4].
Racotumomab (50 μg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model[2].
Racotumomab (50 μg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft[3].
Racotumomab (50-200 μg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft[3].
| Catalog Number | I042527 |
| CAS Number | 946832-34-4 |
| Purity | ≥95% |
| Reference | [1]. Vázquez AM, et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data. Front Oncol. 2012 Oct 23;2:150. [2]. Gajdosik Z. Racotumomab – a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc). 2014 Apr;50(4):301-7. [3]. Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol. 2012 Nov 8;2:160. [4]. Truong CS, et al. Oncolytic Vaccinia Virus in Lung Cancer Vaccines. Vaccines (Basel). 2022 Feb 4;10(2):240. |
